Ballantyne, C. Et Al. 2016. A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C -Density Lipoprotein Cholesterol.. 2016 ESC Cogress .

Ballantyne, C., Shah, S., Sapre, A., Ashraf, A., Tobias, S., ŞAHİN, T., ... Ye, P.(2016). A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C -Density Lipoprotein Cholesterol. . 2016 ESC Cogress

Ballantyne, CM Et Al. "A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C -Density Lipoprotein Cholesterol.," 2016 ESC Cogress, 2016

Ballantyne, CM Et Al. "A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C -Density Lipoprotein Cholesterol.." 2016 ESC Cogress , 2016

Ballantyne, C. Et Al. (2016) . "A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C -Density Lipoprotein Cholesterol.." 2016 ESC Cogress .

@conferencepaper{conferencepaper, author={CM Ballantyne Et Al. }, title={A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C -Density Lipoprotein Cholesterol.}, congress name={2016 ESC Cogress}, city={}, country={}, year={2016}}